EA202191764A1 - Замещенные оксопиридиновые производные - Google Patents
Замещенные оксопиридиновые производныеInfo
- Publication number
- EA202191764A1 EA202191764A1 EA202191764A EA202191764A EA202191764A1 EA 202191764 A1 EA202191764 A1 EA 202191764A1 EA 202191764 A EA202191764 A EA 202191764A EA 202191764 A EA202191764 A EA 202191764A EA 202191764 A1 EA202191764 A1 EA 202191764A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Изобретение относится к замещенным оксопиридиновым производным и способам их получения, а также к их применению для получения лекарственных средств для лечения и/или профилактики заболеваний, в частности сосудистых нарушений, предпочтительно тромботических или тромбоэмболических нарушений, и/или тромботических или тромбоэмболических осложнений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018122825 | 2018-12-21 | ||
PCT/EP2019/085983 WO2020127504A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191764A1 true EA202191764A1 (ru) | 2021-10-22 |
Family
ID=69143542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191764A EA202191764A1 (ru) | 2018-12-21 | 2019-12-18 | Замещенные оксопиридиновые производные |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP3898633A1 (ru) |
JP (1) | JP2022514303A (ru) |
KR (1) | KR20210106504A (ru) |
CN (1) | CN113474348A (ru) |
AR (1) | AR117435A1 (ru) |
AU (1) | AU2019407909B2 (ru) |
BR (1) | BR112021009435A2 (ru) |
CA (1) | CA3124220A1 (ru) |
CL (1) | CL2021001613A1 (ru) |
CO (1) | CO2021007908A2 (ru) |
CR (1) | CR20210342A (ru) |
DO (1) | DOP2021000128A (ru) |
EA (1) | EA202191764A1 (ru) |
EC (1) | ECSP21043895A (ru) |
IL (1) | IL283990A (ru) |
JO (1) | JOP20210161A1 (ru) |
MA (1) | MA54521A (ru) |
MX (1) | MX2021007508A (ru) |
PE (1) | PE20211790A1 (ru) |
SG (1) | SG11202104384PA (ru) |
TW (1) | TW202039510A (ru) |
WO (1) | WO2020127504A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3765452T3 (da) * | 2018-03-15 | 2022-06-27 | Bayer Ag | Fremgangsmåde til fremstilling af to 4-{[(2s)-2-{4-[5-chlor-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorbenzamidderivater |
CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
CR20230431A (es) | 2021-03-09 | 2023-10-27 | Bayer Ag | Formas de dosificación farmacéuticas que comprenden (4S)–24–cloro–4–etil–73–fluoro–35– metoxi–32,5–dioxo–14–(trifluorometil)–32H–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola– 2(1,2),7(1) dibencenaheptafano–74–carboxamida |
WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
US20240174633A1 (en) | 2021-03-09 | 2024-05-30 | Bayer Aktiengesellschaft | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
EP2978425B1 (en) | 2013-03-27 | 2017-09-27 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
CN105555767B (zh) | 2013-07-23 | 2018-03-23 | 拜耳制药股份公司 | 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途 |
US9765070B2 (en) | 2013-10-30 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
CN106687458B (zh) | 2014-09-24 | 2020-10-27 | 拜耳制药股份公司 | 取代的氧代吡啶衍生物 |
WO2016046158A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
EP3197891B1 (de) * | 2014-09-24 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate |
WO2016046156A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
WO2016046166A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
JP2018509426A (ja) * | 2015-03-19 | 2018-04-05 | バイエル ファーマ アクチエンゲゼルシャフト | 血栓症の治療のための因子XIa阻害剤としてのオキソピリジン誘導体 |
JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
WO2017037051A1 (de) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en active Active
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN113474348A (zh) | 2021-10-01 |
CO2021007908A2 (es) | 2021-07-19 |
MX2021007508A (es) | 2021-08-05 |
BR112021009435A2 (pt) | 2021-08-17 |
EP3898633A1 (en) | 2021-10-27 |
TW202039510A (zh) | 2020-11-01 |
AR117435A1 (es) | 2021-08-04 |
KR20210106504A (ko) | 2021-08-30 |
AU2019407909A1 (en) | 2021-05-27 |
JOP20210161A1 (ar) | 2023-01-30 |
SG11202104384PA (en) | 2021-05-28 |
JP2022514303A (ja) | 2022-02-10 |
CA3124220A1 (en) | 2020-06-25 |
AU2019407909B2 (en) | 2023-05-25 |
ECSP21043895A (es) | 2021-07-30 |
CL2021001613A1 (es) | 2021-12-03 |
IL283990A (en) | 2021-07-29 |
DOP2021000128A (es) | 2021-09-30 |
MA54521A (fr) | 2022-03-30 |
PE20211790A1 (es) | 2021-09-09 |
WO2020127504A1 (en) | 2020-06-25 |
CR20210342A (es) | 2021-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202191764A1 (ru) | Замещенные оксопиридиновые производные | |
EA201890111A1 (ru) | Замещенные производные оксопиридина | |
EA202092779A1 (ru) | Замещенные дигидропиразолопиразинкарбоксамидные производные | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
MY195561A (en) | Indole Carboxamide Compounds useful as Kinase Inhibitors | |
EA201791507A1 (ru) | Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7 | |
EA201792354A1 (ru) | Композиции обетихолевой кислоты и способы применения | |
EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
EA202091708A1 (ru) | Ингибиторы днк-пк | |
EA201600288A1 (ru) | Замещенные фенилаланиновые производные | |
EA202191122A1 (ru) | СЕЛЕКТИВНЫЕ К RGMc ИНГИБИТОРЫ И ИХ ПРИМЕНЕНИЕ | |
CY1124492T1 (el) | 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων | |
EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EA202091655A1 (ru) | Композиции и способы лечения нарушений сетчатки | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
EA202191115A1 (ru) | Новые пиридазины | |
EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
EA202092045A1 (ru) | Лечение и предупреждение преэклампсии | |
EA201692051A1 (ru) | Арилзамещенные гетероциклилсульфоны |